Anatomical and Functional Approaches for Bifurcation Lesions "CROSS and PERFECT" Trials

Young-Hak Kim, MD, PhD,

On behalf of CROSS and PERFECT investigators. Heart Institute, University of Ulsan College of Medicine Asan Medical Center, Seoul, Korea

### **Disclosure Information**

Supported by research grants from the Korean Society of Interventional Cardiology & CardioVascular Research Foundation (CVRF)

No industry sponsorship relevant to this study







# SYNTAX Bifurcation Substudy Bifurcation / Trifurcation Subset



\*Medina Classification not available at study design

# **Current RCTs for Bifurcation Lesions** Evaluation of the Benefit of Complex Stenting

Trials	Main Purpose
NORDIC 1	Provisional T vs. Systemic T stenting
NORDIC 2	Crush vs. Culotte
NORDIC 3	Kissing balloon vs. leave alone
CACTUS	Provisional T vs. Crush



### Nordic 1 trial (413 pts) Single vs. Two



# NORDIC 2 trial (425 pts) Crush vs. Culotte



### NORDIC 3 trial (477 pts) Kissing vs. No kissing 6-month composite of death, MI, TLR, and ST



### CACTUS trial (350 pts) **Provisional T vs. Crush** 6-Month In-segment Restenosis



### **ZEST Bifurcation Substudy** 25% of all lesions had bifurcations



### Fate of SB Stenosis in Overall Improve or steady in 91%



# **Message from Trials**

Keep it simple ! because there is no difference in clinical outcomes across the diverse bifurcation stenting strategies.





# However, there are still lots of uncertainties in ...

- Those requiring 2-stent technique ?
- Time for kiss ?
- Time to shift to 2-stent from 1-stent ?
- Impact of non-compliant balloon ?
- Benefit of IVUS-guidance ?
- Outcomes of FFR in side branch ?
- Etc...





### When we need two stents in provisional stenting? % of Cross-over to 2-Stent from 1-stent



### **CROSS & PERFECT Trials** to assess IVUS-Guided Bifurcation Stenting







### <u>Choice of optimal stRategy fOr bifurcation leSions</u> with normal Side branch <u>CROSS Trial</u> Bifurcations without SB Stenosis







CardioVascular Research Foundation

# **Inclusion Criteria**

### 1. Clinical

- Objective evidence of ischemia
- Age >18 years, <75 ages</p>

### 2. Angiographic

- De novo with the MEDINA type 1.1.0, 1.0.0, or 0.1.0
- MB:  $\geq$  2.5 mm,  $\geq$  50% and  $\leq$  50 mm by visual estimation
- SB:  $\geq$  2.0 mm and < 50%





# **Exclusion Criteria**

- Significant comorbidity
- STEMI  $\leq$  2 weeks
- Characteristics of lesion
  - Left main disease
  - In-stent restenosis
  - Graft vessels
  - TIMI flow  $\leq$  grade 2 in the SB
  - **-** СТО
- Chronic renal failure



# CROSS Trial Study Design

- Primary end points
  - 8-month diameter stenosis in SB

### Design and hypothesis

 The 'leave alone strategy' is not inferior to 'kissing balloon'





### FFR and IVUS are mandatory to assess the mechanisms of phenomena occurring in bifurcations after stenting



### Stenting techniques classified by EBC



**Medical Center** 

### **Tracking the All Steps of Procedure**

CROSS

Home New Case Subject List Adjudication

Angiographic & Procedural Stent Technique 2 노진석(서울마산병원) 로그이오 관리자 문의하기

010005 HGD 2007-04-24

#### Patient Information

- Baseline Clinical Data
- Medical History & Risk Factor - Diagnosis & Exam

#### Angiographic & Procedural

- Patient Level Information - Target Bifurcation Data
- Stenting Technique1
- Stenting Technique2

#### Medication

- Antiplatelet Medication - Other Concomitant Medication

#### Laboratory Value

- In-hospital Laboratory

#### Clinical Outcomes

- In-hospital Outcomes
- 30days FU Outcomes
- 6Month FU Outcomes
- 9Month FU Outcomes - FU Angiographic & Exam
- 12Month FU Outcomes
- 2year FU Outcomes

#### Bleeding

#### - Bleeding

- Adverse Event
- Adverse Event

#### Major Adverse Event

- Death - Myocardial Infarction
- Repeat Revascularization
- Stent Thrombosis

Performance Performance Sequence Procedure Sequence Procedure TAP 1\* MB wiring TAP 8\* SB rewiring after MB stenting O Done O ND O Done O ND TAP 2\* TAP 9\* SB wiring O Done O ND Kissing after MB stenting O Done O ND TAP 3\* MB predilation **TAP10\*** SB stenting O Done O ND O Done O ND TAP 4\* SB predilation O Done O ND TAP 11\* SB balloon dilatation O Done O ND TAP 5\* **TAP12**\* **Kissing predilation** MB balloon dilatation O Done O ND O Done O ND **TAP 6**\* MB stenting TAP13 \* Final kissing O Done O ND O Done O ND MB in-stent HP TAP 7\* dilatation with short O Done O ND balloon



### O<u>P</u>timal St<u>E</u>nting St<u>R</u>ategy <u>F</u>or Tru<u>E</u> Bifur<u>C</u>a<u>T</u>ion</u> **PERFECT Trial**

**Bifurcations with SB Stenosis** 







# **Inclusion Criteria**

### 1. Clinical

- Objective evidence of ischemia
- Age >18 years, <75 ages</p>

### 2. Angiographic

- De novo with the MEDINA type 1.1.1, 1.0.1, or 0.1.1
- MB:  $\geq$  2.5 mm,  $\geq$  50% and  $\leq$  50 mm
- SB:  $\geq$  2.0 mm,  $\geq$  50%, and < 20 mm





# PERFECT Trial Study Design

- Primary end point
  - 8-month overall restenosis rate in MB or SB

- Hypothesis for sample size estimation
  - The provisional T is not inferior to the routine Crush technique







## **Crush & Kiss** with non-compliant balloons

010005 HGD 2007-04-24		giographic & Proced lassic Crush	ural			
Patient Information	Sequence	Procedure	Performance	Sequence	Procedure	Performance
Baseline Clinical Data	Classic Crush 1 *	MB wiring	🔘 Done 🔘 ND	Classic Crush 8 *	MB stenting (Crush SB stent)	O Done O NE
agnosis & Exam	Classic Crush 2*	SB wiring	O Done O ND	Classic Crush 9 *	SB rewiring	O Done O NE
ngiographic & Procedural	Classic Crush 3 *	MB predilation	💿 Done 💿 ND	Classic Crush 10 *	SB ballooning by small balloon	🖱 Done 🖱 NE
Patient Level Information Target Bifurcation Data Stenting Technique Simple Stenting	Classic Crush 4 *	SB predilation	O Done O ND	Classic Crush 11*	SB high pressure dilatation	🔘 Done 🔘 NE
	Classic Crush 5 *	Kissing predilation	🖱 Done 🖱 ND	Classic Crush 12 *	MB high	🔘 Done 🔘 NE
ovisional T Stenting assic Crush	Classic Crush 6 *	SB stenting (MB stent backup)	🗇 Done 🔘 ND	Classic Crush 13 *	Final kissing dilatation	🔘 Done 🔘 NE
illoon Crush her Technique	Classic Crush 7 *	SB balloon and	🔊 Done 🔘 ND			
Ionth FU Outcomes Ionth FU Outcomes J Angiographic & Exam 2Month FU Outcomes	Classic Crush 8	Classic Crush 9	Classic Crush 10 Cl	lassic Crush11 Clas	sic Crush 12 Classic Crush 1	1 <sup>0</sup> / V
ear FU Outcomes leeding eeding	Л	Л	Such	(HP)		
dverse Event Verse Event		1 41		IXIA	$(\Lambda)$	
lajor Adverse Event eath /ocardial Infarction anast Revise gularization	Did you perform u If you didn't, choo	wire recross after cru se why as shown bel	Ish (Classic crush S low. *? ross O Other	)? Please clarify,		1

D

Ð

LSAN



# QCA using dedicated software and IVUS analysis in the Core Lab

Bifurcation Segment Model		
C		
JEONG HYEONG JIN	27258695	Ref A
Birthdate	1931-4-8	Carina 4.55
Physician Hospital Acquisition Date	Asan Medical Center/4411	
	Asali Medical Centen4411.	Ratio DisuProx at Ostum
	2006-9-7	Murray
Patient Orientation II Size	2006-9-7 L\F 16.00 cm	Rado Disorriox at Ostulm Lumm Murray Finet Prox pos Length \$0 Mi (mm) (%) (m
Patient Orientation II Size Segment Trial Name	2006-9-7 L\F 16.00 cm	Prox pos         Length         K0         Min           1         0.00         4.97         7.16         1
Patient Orientation II Size Segment Trial Name Intervention	Asan Medical Center,4411. 2006-9-7 L\F 16.00 cm	Prox pos         Length         K0         Min           1         0.00         4.97         7.16         1           2         4.97         2.09         4.05         1
Patient Orientation II Size Segment Trial Name Intervention Analysis type Cal. Factor	2006-9-7 L\F 16.00 cm Nonostial 0.1339 mm/bix	Prox pos         Length         KD         Min           Prox pos         Length         KD         Min           1         0.00         4.97         7.16         1           2         4.97         2.59         4.56         1           3         7.66         8.23         38.29         0           4         15.80         4.98         16.54         1
Patient Orientation II Size Segment Trial Name Intervention Analysis type Cal. Factor Cal. Object	2006-9-7 L\F 16.00 cm Nonostial 0.1339 mm/pix 7.00 French Catheter	Prox pos         Length         %0         Min           1         0.00         4.97         7.16         1           2         4.97         2.59         4.56         1           3         7.68         4.58         1           5         7.67         6.91         19.84         1
Patient Orientation II Size Segment Trial Name Intervention Analysis type Cal. Factor Cal. Object	2006-9-7 L\F 16.00 cm Nonostial 0.1339 mm/pix 7.00 French Catheter	Prox pos         Length         %0         Min           Prox pos         Length         %0         Min           1         0.00         4.97         7.16         1           2         4.97         2.59         4.66         1           3         7.56         8.23         38.29         0           4         16.80         4.98         16.54         1           5         7.67         6.91         19.84         1           8         13.68         5.00         11.07         1           7         Main         5.58         4.96         1
Patient Orientation II Size Segment Trial Name Intervention Analysis type Cal. Factor Cal. Object	2006-9-7 L\F 16.00 cm Nonostial 0.1339 mm/pix 7.00 French Catheter	Prox pos         Length         %0         Min           Prox pos         Length         %0         Min           1         0.00         4.97         7.16         1           2         4.97         2.69         4.66         1           3         7.56         8.23         38.29         0           4         15.80         4.98         16.54         1           5         7.67         6.91         19.84         1           6         13.68         5.00         11.07         1           7         Main 5.13         2.54         4.56         1           7         Side         6.13         2.54         4.56
Patient Orientation II Size Segment Trial Name Intervention Analysis type Cal. Factor Cal. Object	2006-9-7 L\F 16.00 cm Nonostial 0.1339 mm/pix 7.00 French Catheter	Prox pos         Length         %D         Mit           Prox pos         Length         %D         Mit           1         0.00         4.97         7.16         1           2         4.97         2.69         4.66         1           3         7.56         8.23         38.29         0           4         16.80         4.38         16.54         1           5         7.67         6.91         13.88         6.00         11.07           1         7.86         6.13         2.54         4.56         1           7         Main 5.18         2.54         4.56         1           7         Side         5.13         2.54         4.56           8         7.67         2.03         19.84         1           6         7.13         2.54         4.56         1           8         7.67         2.03         19.84         1           8         7.67         2.03         19.84         1           8         7.67         2.03         19.84         1           9         7.67         2.03         19.84         1







# Preliminary **Personal Experiences**





CardioVascular Research Foundation

### **CROSS Patient** *Treated with Endeavor 3.0 X 24 mm*

Pre-



### **Post-stenting**







### **MB IVUS after Procedure**



CardioVascular Research Foundation



- Negative remodeling in short SB stenosis was very often.
- Both plaque and carina shifts contributed to the SB compromise.
- The FFR at SB after stenting was > 0.8 in more than 90%.
- Provisional SB stenting was performed in < 5% of patients.





# Randomized to Provisional Stenting in the PERFECT trial



# **3-D Morphology**



# **Stenting in the Main Branch**





The procedure was getting worse...

etta correct menone

Cieffy mental centre

### **Difficult Wiring and TAP** (Minimal Protrusion of SB stent with T-technique)







CardioVascular Research Foundation



# **Procedure Time**



# **Amount of Contrast Agent**



### Importance of IVUS-guided Procedure Randomized to Provisional Stenting in the PERFECT trial





# **Single-Stent with Final Kissing**

![](_page_45_Picture_1.jpeg)

CardioVascular Research Foundation

![](_page_45_Picture_3.jpeg)

![](_page_45_Picture_4.jpeg)

# From CROSS and PERFECT

We hope to reveal that a careful anatomical & functional evaluation provide very useful information improving the outcomes of PCI with DES for bifurcation coronary lesions.

![](_page_46_Picture_3.jpeg)